The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC).
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Joanne Xiu
Employment - Caris Life Sciences
 
Yasmine Baca
Employment - Caris Life Sciences
 
Phillip Walker
Employment - Caris Life Sciences
 
Gulam Abbas Manji
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - BiolineRx; CEND Pharmaceuticals; Exelixis; Ipsen; Roche/Genentech
Research Funding - BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Sepideh Gholami
Consulting or Advisory Role - Helsinn Healthcare; QED Therapeutics; Signatera
Speakers' Bureau - Helsinn Therapeutics
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Ajay Prakash
No Relationships to Disclose
 
Igor A. Astsaturov
Honoraria - Caris Life Sciences
Consulting or Advisory Role - Caris Life Sciences; Guardant Health
Speakers' Bureau - Caris Life Sciences
Research Funding - Lantern Pharma
 
Greg Botta
No Relationships to Disclose
 
Laith I. Abushahin
Research Funding - Celgene (Inst)
 
Davendra Sohal
Honoraria - Foundation Medicine
Consulting or Advisory Role - Ability Pharma; AstraZeneca/MedImmune; Perthera
Speakers' Bureau - Genentech; Incyte
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); FibroGen (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst)
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics
Research Funding - D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
 
Andreas Seeber
Consulting or Advisory Role - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences